Codrituzumab (GC33) 是一种靶向人类 GPC3 (磷脂酰肌醇蛋白聚糖-3) 的人源化单克隆抗体，具有高亲和力 (Kd 为 0.673 nM)。GPC3 是一种在肝细胞癌 (HCC) 细胞表面表达的癌胚蛋白。Codrituzumab 可诱导抗体依赖性细胞毒性 (ADCC) 并抑制肿瘤生长。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab-MMAE) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.

The purity of Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab-MMAE) is 99.73%, determined by SEC-HPLC.

MMAE is conjugated by sulfhydryl coupling,the DAR value of Anti TROP2 Reference Antibody (Sacituzumab govitecan) antibody is 3.8.

Human GPC3 / Glypican-3 HEK293 Cell Line were stained Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab-MMAE) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.35 ug/mL.

The killing ratio Codrituzumab-MMAE by HuH-7 increased with the increase of antibody concentration, and the killing Rate (%) reached 130% at antibody concentration of 40 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.